Compare DEI & COAG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DEI | COAG |
|---|---|---|
| Founded | 1971 | 2020 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.9B | 1.9B |
| IPO Year | 2006 | 2026 |
| Metric | DEI | COAG |
|---|---|---|
| Price | $10.18 | $35.72 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 12 | 6 |
| Target Price | $12.40 | ★ $62.67 |
| AVG Volume (30 Days) | ★ 2.0M | 346.6K |
| Earning Date | 11-03-2026 | 11-05-2026 |
| Dividend Yield | ★ 7.47% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,003,982,000.00 | N/A |
| Revenue This Year | $1.79 | N/A |
| Revenue Next Year | $2.61 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 1.77 | N/A |
| 52 Week Low | $9.04 | $27.38 |
| 52 Week High | $13.32 | $55.42 |
| Indicator | DEI | COAG |
|---|---|---|
| Relative Strength Index (RSI) | 53.43 | 54.18 |
| Support Level | $9.30 | $28.46 |
| Resistance Level | $10.59 | $38.87 |
| Average True Range (ATR) | 0.32 | 2.49 |
| MACD | 0.12 | 1.06 |
| Stochastic Oscillator | 88.52 | 90.18 |
Douglas Emmett Inc is an integrated, self-administered, and self-managed REIT. The group focuses on owning, acquiring, developing, and managing a substantial market share of office properties and multifamily communities in neighborhoods with supply constraints, high-end executive housing, and key lifestyle amenities. Its properties are located in the Beverly Hills, Brentwood, Burbank, Century City, Olympic Corridor, Santa Monica, Sherman Oaks/Encino, Warner Center/Woodland Hills and Westwood submarkets of Los Angeles County, California, and in Honolulu, Hawaii. It has two business segments: the office segment and multifamily segment, of which Office segment derives maximum revenue.
Hemab Therapeutics Holdings Inc is a clinical-stage biotechnology company developing therapies for the treatment of blood coagulation disorders. It focuses on discovering, developing, and commercializing treatments for conditions such as Glanzmann thrombasthenia, Factor VII deficiency, and von Willebrand disease. Its flagship candidate, sutacimig (HMB-001), is a bispecific antibody currently in clinical trials for the prophylactic treatment of Glanzmann thrombasthenia and Factor VII deficiency. The company has one operating segment, engaged in the research and development of prophylactic therapeutics for bleeding disorders.